<< Back to News

System Formulary Update
Donanemab-azbt (Kisunla)

Situation: Donanemab-azbt (Kisunla) was approved for addition to the UNC Health System Formulary at the System Pharmacy and Therapeutics Committee meeting. 

Background: The following medication was reviewed: donanemab-azbt (Kisunla) 17.5 mg/mL Intravenous Solution 

Assessment/Recommendations: System P&T voted to include donanemab-azbt (Kisunla) 17.5 mg/mL intravenous solution on the UNC Health System Formulary with the following restrictions: 

• Restricted to outpatient/clinic encounters only (i.e., no inpatient use)
• A benefits investigation must be completed prior to use
• Cannot be initiated in patients who:
• Are ApoE4 homozygous (ApoE4 status must be confirmed prior to initiation)
• Have had a TIA/CVA in the past 6 months prior to initiation 
• Orders must be signed by a neurology attending physician at designated clinics, including the following:
• UNC Hospitals Neurology Clinic (Aging Brain Clinic)
• Pardee Neurology Associates (Hendersonville or Arden locations)
• Boone Neurological Services
• High Country Neurology

Formulary/Epic Changes will Go-Live on Tuesday, December 17, 2024.